Shield Therapeutics announces the US New Drug Application PDUFA date for Feraccru®

17 Dec 2018

Shield Therapeutics plc announces that the US Food and Drug Administration (FDA) has confirmed that the target date for completion of the New Drug Application (NDA) review of Feraccru, under the terms of the Prescription Drug User Fee Act (PDUFA), is 27 July 2019.

For further details please see the press release below:

Press Release

Back to news